Revive Therapeutics Ltd (RVVTF)

$0.01 0.00 (N/A)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 32,300
Avg Vol 329,510
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 5%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It develops Bucillamine, a disease-modifying anti-rheumatic drug, for the treatment of infectious diseases, including influenza and COVID-19, as well as to treat pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks. The company also develops Psilocybin, which i...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 888-901-0036
Fax: 905-248-3355
Address:
The Canadian Venture Building, 82 Richmond Street East, Toronto, Canada
MarcoPolo12
MarcoPolo12 Feb. 5 at 4:43 PM
$RVVTF February, still no update Could mean literally anything - but nothing gets released before DRDC clearance which could take time Anon sells were heavy on the Canadian side yesterday, investor patience running thin?
3 · Reply
Canadianbull1324
Canadianbull1324 Feb. 5 at 1:15 PM
$RVVTF RVV is sitting at $0.01 with microscopic volume. Microcaps at this level behave like dry tinder — any spark can ignite a move. Best‑case price reaction window (based on historical microcap patterns): The absolute ceiling in a best case is around $0.10–$0.15. Anything beyond that would require a transformational announcement, not just “positive results.”
1 · Reply
Retirement2025
Retirement2025 Feb. 4 at 7:03 PM
$RVVTF with this quick volume, I feel good news is around the corner. Just my opinion!
1 · Reply
Tartufo
Tartufo Feb. 4 at 5:12 PM
$RVVTF why so many shares traded out of nowhere?
2 · Reply
Canadianbull1324
Canadianbull1324 Feb. 4 at 4:37 PM
$RVVTF at this point they owe us notice of whether the study concluded or not, at a minimum.
0 · Reply
Bobertt
Bobertt Feb. 4 at 2:42 AM
$RVVTF The last update said results were expected in January so they are probably still reviewing the results right now. They did however state it's up to the DRDC if they publicly announce the results so there is a chance we don't get the results for several months.
5 · Reply
Dirtymartini66
Dirtymartini66 Feb. 2 at 2:48 PM
$RVVTF ready for great news! King me!
1 · Reply
BobWarner99
BobWarner99 Feb. 2 at 2:34 PM
$RVVTF One day we'll get news whether it's good, bad or mediocre. But until then.... https://youtu.be/uMyCa35_mOg?si=L0uAkRr6HpfhHrM0
0 · Reply
Canadianbull1324
Canadianbull1324 Feb. 2 at 2:09 PM
$RVVTF Why It’s Being Studied for Nerve Agent Exposure 1. Targets secondary brain injury Current nerve agent treatments (atropine, pralidoxime, benzodiazepines) focus on: • Reversing acetylcholinesterase inhibition • Controlling seizures • Managing acute symptoms They do not fully prevent long‑term neurological damage caused by oxidative stress and inflammation. Bucillamine specifically targets these secondary injury pathways. 2. Potential to reduce long‑term neurological effects Canadian Defence R&D (DRDC) is evaluating Bucillamine for its ability to: • Protect the brain after exposure • Reduce chronic neurological symptoms • Improve outcomes beyond what standard antidotes achieve 3. Promising early research • DRDC and Revive Therapeutics are conducting studies to validate Bucillamine’s neuroprotective effects after nerve agent exposure. • The research is significant enough that stockpiling potential is already being discussed.
0 · Reply
Canadianbull1324
Canadianbull1324 Jan. 30 at 6:11 PM
$RVVTF If we get good news we will never see these levels again. Happy Friday and GLTA
4 · Reply
Latest News on RVVTF
No data available.
MarcoPolo12
MarcoPolo12 Feb. 5 at 4:43 PM
$RVVTF February, still no update Could mean literally anything - but nothing gets released before DRDC clearance which could take time Anon sells were heavy on the Canadian side yesterday, investor patience running thin?
3 · Reply
Canadianbull1324
Canadianbull1324 Feb. 5 at 1:15 PM
$RVVTF RVV is sitting at $0.01 with microscopic volume. Microcaps at this level behave like dry tinder — any spark can ignite a move. Best‑case price reaction window (based on historical microcap patterns): The absolute ceiling in a best case is around $0.10–$0.15. Anything beyond that would require a transformational announcement, not just “positive results.”
1 · Reply
Retirement2025
Retirement2025 Feb. 4 at 7:03 PM
$RVVTF with this quick volume, I feel good news is around the corner. Just my opinion!
1 · Reply
Tartufo
Tartufo Feb. 4 at 5:12 PM
$RVVTF why so many shares traded out of nowhere?
2 · Reply
Canadianbull1324
Canadianbull1324 Feb. 4 at 4:37 PM
$RVVTF at this point they owe us notice of whether the study concluded or not, at a minimum.
0 · Reply
Bobertt
Bobertt Feb. 4 at 2:42 AM
$RVVTF The last update said results were expected in January so they are probably still reviewing the results right now. They did however state it's up to the DRDC if they publicly announce the results so there is a chance we don't get the results for several months.
5 · Reply
Dirtymartini66
Dirtymartini66 Feb. 2 at 2:48 PM
$RVVTF ready for great news! King me!
1 · Reply
BobWarner99
BobWarner99 Feb. 2 at 2:34 PM
$RVVTF One day we'll get news whether it's good, bad or mediocre. But until then.... https://youtu.be/uMyCa35_mOg?si=L0uAkRr6HpfhHrM0
0 · Reply
Canadianbull1324
Canadianbull1324 Feb. 2 at 2:09 PM
$RVVTF Why It’s Being Studied for Nerve Agent Exposure 1. Targets secondary brain injury Current nerve agent treatments (atropine, pralidoxime, benzodiazepines) focus on: • Reversing acetylcholinesterase inhibition • Controlling seizures • Managing acute symptoms They do not fully prevent long‑term neurological damage caused by oxidative stress and inflammation. Bucillamine specifically targets these secondary injury pathways. 2. Potential to reduce long‑term neurological effects Canadian Defence R&D (DRDC) is evaluating Bucillamine for its ability to: • Protect the brain after exposure • Reduce chronic neurological symptoms • Improve outcomes beyond what standard antidotes achieve 3. Promising early research • DRDC and Revive Therapeutics are conducting studies to validate Bucillamine’s neuroprotective effects after nerve agent exposure. • The research is significant enough that stockpiling potential is already being discussed.
0 · Reply
Canadianbull1324
Canadianbull1324 Jan. 30 at 6:11 PM
$RVVTF If we get good news we will never see these levels again. Happy Friday and GLTA
4 · Reply
2014shelby
2014shelby Jan. 30 at 3:14 PM
$RVVTF From December 15, 2025 PR: “After recent discussions with the DRDC, the research study on Bucillamine is expected to conclude with results in January 2026. Any findings from the study will be released only with the express authorization of DRDC. Revive will continue to provide updates on the DRDC study as it advances toward completion.” Would be nice to get an update today from Revive GLTA shareholders
1 · Reply
Canadianbull1324
Canadianbull1324 Jan. 30 at 2:11 PM
$RVVTF pump pump pump
0 · Reply
BobWarner99
BobWarner99 Jan. 30 at 12:40 AM
$RVVTF Very low expectations for Friday January 30th 2026. I will be pleasantly surprised if we do get an very positive update tomorrow. After rereading the last PR, it says the research study is 'expected' to concluded by January 2026. It says nothing about when the news of the research study will drop. So, I'm we'll get news in February 2026?? We'll see.
0 · Reply
Canadianbull1324
Canadianbull1324 Jan. 29 at 4:07 PM
$RVVTF no news again, sweet
1 · Reply
Bull80
Bull80 Jan. 29 at 4:02 PM
$RVVTF Looks like no news again or may be a PR that will say end of Feb, lol
2 · Reply
Canadianbull1324
Canadianbull1324 Jan. 28 at 5:14 PM
$RVVTF
8 · Reply
BobWarner99
BobWarner99 Jan. 28 at 3:07 PM
$RVVTF If the results are expected in January 2026. Whatever type of updates the market gets wouldn't signed off by DRDC and given to MF to PR until February 2026???
0 · Reply
Canadianbull1324
Canadianbull1324 Jan. 28 at 12:38 PM
$RVVTF let's goooooo
0 · Reply
BobWarner99
BobWarner99 Jan. 27 at 4:15 PM
$RVVTF The most recent update PR only mentions January 2026. Not any actual date. Keep in mind it does say expected...as Safe Harbor word. So we'll see if we get news good or bad by Friday the 30th. Unless they release an update on the very last day of January, Saturday the 31st 2026. 😳 https://finance.yahoo.com/news/revive-therapeutics-provides-key-nerve-123000738.html "After recent discussions with the DRDC, the research study on Bucillamine is expected to conclude with results in January 2026. Any findings from the study will be released only with the express authorization of DRDC. Revive will continue to provide updates on the DRDC study as it advances toward completion."
1 · Reply
Tartufo
Tartufo Jan. 27 at 4:04 PM
$RVVTF wow heavy trading day LOL
0 · Reply
Retirement2025
Retirement2025 Jan. 27 at 2:39 PM
$RVVTF Well January 26th news didn't happen! Here's hoping for January 30th...we are running out of days for January!
2 · Reply
Canadianbull1324
Canadianbull1324 Jan. 27 at 2:36 PM
$RVVTF this week could be make or break!!! let's goooo
0 · Reply